Defiance Leveraged Long +Income HIMS ETF

Hims & Hers Health Increases Convertible Note Offering to $350 Million

Hims & Hers Health Average Target Price Rises to $27.51

JPMorgan Downgrades Hims & Hers Health's Price Target to $33

Hims & Hers Health Misses Q1 Earnings Estimates, Shares Fall

Oppenheimer & Co. Significantly Reduces Holdings in Hims & Hers Health

Hims & Hers Health's Chief Legal Officer Sold Company Stocks

Hims & Hers Reports FY2025 Revenue and FY2026 Forecast

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

Hims & Hers Massive Stock Drop Explained

HIMS

HIMZ

HIMY

Hims & Hers is raising $350 million through a convertible debt offering, which may limit shareholder dilution but also increases business risk. The company must demonstrate growth potential to the market, as the debt could either convert to stock or require cash repayment. This move aims to fund long-term growth plans.

nasdaq

Hims & Hers Health

Defiance Daily Target 2X Long HIMS ETF

VG Health

iShares US Healthcare Providers

SPDR S&P Health

NVIDIA

Intel

S&P 500

Nasdaq

NVIDIA Corporation

Bank of America has lowered its price target for Hims & Hers Health (NYSE:HIMS) from $30.00 to $28.00, maintaining a 'neutral' rating. This suggests a potential upside of 25.44% from the current price. Other analysts have also adjusted their ratings, with Morgan Stanley setting a target of $21.00 and Citigroup raising it to $28.00. Hims & Hers Health's stock is currently trading at $22.32.

Market Beat

iShares Global Healthcare

Bank of America

Morgan Stanley

Citigroup

Novo Nordisk AS

Eli Lilly

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Bank of America Lowers Hims & Hers Health (NYSE:HIMS) Price Target to $28.00

Hims & Hers Health reported disappointing Q1 results, leading to a 14.07% drop in shares. Revenue was $608 million, missing estimates, while EBITDA fell to $44.3 million. Analysts had mixed reactions: JPMorgan maintained an Overweight rating but lowered the price target to $33; Needham kept a Buy rating and raised the target to $35; BTIG reaffirmed a Neutral rating. The company raised its 2026 revenue outlook despite lowering EBITDA guidance by $25 million, citing concerns over margin pressure from the shift to branded GLP-1s.

benzinga_article

JPMorgan Chase

OpenAI

Shutterstock

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts

ASTS

U.S. stock futures fell on Tuesday due to a higher-than-expected April inflation reading of 3.8%. The Nasdaq 100, S&P 500, and Dow Jones futures dropped by 0.94%, 0.43%, and 0.08%, respectively. Oil prices rose amid ongoing U.S.-Iran tensions, with Brent crude up 3.46%. In pre-market trading, Under Armour, Hims & Hers Health, and AST SpaceMobile stocks saw significant declines, while Wendy's stock surged over 16% following news of potential privatization efforts by Trian Fund Management.

Tip Ranks

Under Armour-C

AST SpaceMobile

Wendys

NASDAQ-100

Dow Jones Industrial Average

Invesco QQQ Trust

NASDAQ Composite Index

Under Armour

GitLab

U.S. Stock Futures Fall on April Inflation Reading, Persistent Geopolitical Tensions

ARMK

EATZ

Top Wall Street analysts have updated their ratings on several companies. Baird raised Aramark's price target from $50 to $58, maintaining an Outperform rating, while Aramark shares closed at $48.41. Other notable changes include BMO Capital increasing Nextpower's target from $113 to $125, and Mizuho cutting Agree Realty's target from $86 to $80. Analysts also adjusted targets for companies like Arvinas, Intellia Therapeutics, and Hims & Hers Health. For a complete list of changes, see the analyst ratings page.

Aramark

AdvisorShares Restaurant ETF

Nextpower

Agree Realty

Arvinas

Intellia Therap

Sensata Tech

ZoomInfo Tech

Aecom

Arteris

AGREE REALTY CORP DEP SHS EA REP 1/1000 CUM PFD STK SR A

Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Hims & Hers Health reported Q1 earnings impacted by margin pressure but anticipates increased revenue for Q2. The company is experiencing stability that could lead to a market squeeze. Recent FDA rulings on GLP-1 compounding may benefit Hims, and a rating upgrade is noted. Additionally, insights on shorted healthcare stocks are provided.

Health Care Select Sector SPDR

Earnings snapshot: Hims & Hers Health Q1 earnings hit by margin pressure; lifts Q2 revenue

Hims & Hers Health, Inc. stock's average price target has increased from $27.17 to $27.51, indicating a potential downside of approximately 6% based on the May 11 closing price. The consensus rating remains a "Buy" among 20 analysts, with 7 Buys, 13 Holds, and no Sells. Forecasts for the stock range from $18 to $35 per share.

TradingView

Factset Research

Hims & Hers Health, Inc. Stock 12‑Month Price Target Raised to $27.51, Implies 6% Downside

Analyst Craig Hettenbach of Morgan Stanley has maintained a Hold rating on Hims & Hers Health, reiterating a price target of $21.00. The decision is based on the company's aggressive revenue expansion efforts, which are accompanied by reduced EBITDA guidance and declining gross margins, indicating profitability pressures. Despite a strong top-line performance, the company missed its first EBITDA expectations. Citi also assigned a Hold rating with a $28.00 price target, reflecting concerns over sustainable margin improvement and positive EBITDA revisions.

Hims & Hers Health: Hold Maintained as Profitability Pressures Offset Growth; $21 Price Target Reiterated

Hims & Hers (NYSE:HIMS) reported disappointing Q1 2026 earnings, with an EPS of -$0.40, missing expectations of $0.03. Despite a 4% year-over-year revenue increase to $608 million, the stock fell sharply. Investor Tech Stock Pros remains optimistic, citing a growing subscriber base and a positive Q2 revenue guidance of $680-$700 million. HIMS has a consensus Hold rating from Wall Street, with a 12-month price target of $29.22, indicating a 17% upside.

'An Attractive Opportunity,' Says Top Investor About Hims & Hers Stock

Oppenheimer & Co. Inc. has significantly reduced its holdings in Hims & Hers Health, Inc. by 83.8%, owning 7,254 shares after selling 37,448 shares in Q4. Other hedge funds have also adjusted their positions, with notable increases from Pathway Capital Management and Steadview Capital Management. Hims & Hers Health's stock opened at $28.46, with a market cap of $6.49 billion and a recent EPS of $0.08, surpassing estimates. Analysts have mixed ratings, with price targets ranging from $18.00 to $30.00.

Oppenheimer

Truist Financial

Barclays

Amazon

Oppenheimer & Co. Inc. Cuts Holdings in Hims & Hers Health, Inc. $HIMS

Barclays analyst Glen Santangelo has maintained a Buy rating on Hims & Hers Health (HIMS) with a price target of $29.00. Santangelo, a 4-star analyst, has an average return of 3.5% and a 49.50% success rate. Hims & Hers Health also received a Buy rating from J.P. Morgan's Cory Carpenter, while Deutsche Bank assigned a Hold rating on May 5.

Defiance Leveraged Long +Income HIMS ETF(HIMY.US)